[go: up one dir, main page]

CL2018001177A1 - Anticuerpos vinculados especificamente a pd-1 y sus usos. - Google Patents

Anticuerpos vinculados especificamente a pd-1 y sus usos.

Info

Publication number
CL2018001177A1
CL2018001177A1 CL2018001177A CL2018001177A CL2018001177A1 CL 2018001177 A1 CL2018001177 A1 CL 2018001177A1 CL 2018001177 A CL2018001177 A CL 2018001177A CL 2018001177 A CL2018001177 A CL 2018001177A CL 2018001177 A1 CL2018001177 A1 CL 2018001177A1
Authority
CL
Chile
Prior art keywords
antibodies specifically
specifically linked
ident
sec
numbers
Prior art date
Application number
CL2018001177A
Other languages
English (en)
Inventor
Sandra Santulli-Marotto
Raluca Verona
Gordon Powers
Nina Chi Sabins
Nikki A Deangelis
Karla R Wiehagen
Catherine Ferrante
Enrique Zudaire Ubani
Sheng-Jiun Wu
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CL2018001177A1 publication Critical patent/CL2018001177A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C07K16/1145—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UN ANTICUERPO ANTAGONISTA AISLADO QUE SE UNE ESPECÍFICAMENTE A PD-1 O UNA PORCIÓN DE UNIÓN A ANTÍGENO DE ESTE, QUE COMPRENDE UNA REGIÓN DETERMINANTE DE COMPLEMENTARIEDAD DE CADENA PESADA 1 (HCDR1), UNA HCDR2 NI UNA HCDR3 DE LAS SEC. CON NÚMS. DE IDENT.: 82. 83 Y 84, RESPECTIVAMENTE, Y UNA REGIÓN DETERMINANTE DE COMPLEMENTARIEDAD DE CADENA LIGERA 1 (LCDR1), UNA LCDR2 Y UNA LCDR3 DE LAS SEC. CON NÚMS. DE IDENT.: 86. 87 Y 88. RESPECTIVAMENTE.
CL2018001177A 2015-11-03 2018-05-02 Anticuerpos vinculados especificamente a pd-1 y sus usos. CL2018001177A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562250095P 2015-11-03 2015-11-03

Publications (1)

Publication Number Publication Date
CL2018001177A1 true CL2018001177A1 (es) 2018-10-12

Family

ID=58634582

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001177A CL2018001177A1 (es) 2015-11-03 2018-05-02 Anticuerpos vinculados especificamente a pd-1 y sus usos.

Country Status (41)

Country Link
US (3) US10894830B2 (es)
EP (4) EP3370769A4 (es)
JP (6) JP7051692B2 (es)
KR (4) KR102828417B1 (es)
CN (5) CN108697791B (es)
AR (1) AR106583A1 (es)
AU (3) AU2016348388B2 (es)
BR (3) BR112018008891A8 (es)
CA (3) CA3004138A1 (es)
CL (1) CL2018001177A1 (es)
CO (1) CO2018005614A2 (es)
CR (1) CR20180234A (es)
CY (1) CY1125267T1 (es)
DK (1) DK3370768T3 (es)
EA (1) EA201891093A1 (es)
EC (1) ECSP18041833A (es)
ES (1) ES2908376T3 (es)
GT (1) GT201800090A (es)
HR (1) HRP20220436T1 (es)
HU (1) HUE057837T2 (es)
IL (1) IL258909B2 (es)
JO (1) JO3798B1 (es)
LT (1) LT3370768T (es)
MA (1) MA43186B1 (es)
MD (1) MD3370768T2 (es)
MX (3) MX2018005546A (es)
MY (1) MY198562A (es)
NI (1) NI201800055A (es)
PE (1) PE20181326A1 (es)
PH (1) PH12018500906B1 (es)
PL (1) PL3370768T3 (es)
PT (1) PT3370768T (es)
RS (1) RS63125B1 (es)
SG (1) SG11201803520PA (es)
SI (1) SI3370768T1 (es)
SM (1) SMT202200118T1 (es)
SV (1) SV2018005684A (es)
TW (1) TWI772275B (es)
UA (1) UA126896C2 (es)
WO (3) WO2017079112A1 (es)
ZA (1) ZA201803669B (es)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2782218C (en) * 2009-11-30 2018-07-31 Janssen Biotech, Inc. Antibody fc mutants with ablated effector functions
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
EA024701B1 (ru) 2010-04-13 2016-10-31 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
JP5982409B2 (ja) 2011-03-16 2016-09-07 アルゲン−エックス エヌ．ブイ． Ｃｄ７０に対する抗体
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US10508149B2 (en) 2015-04-01 2019-12-17 Anaptysbio, Inc. Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
PT3456346T (pt) 2015-07-30 2021-09-28 Macrogenics Inc Moléculas de ligação pd-1 e lag-3 e respetivos métodos de utilização
EP3337826A1 (en) 2015-08-20 2018-06-27 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
CN108697791B (zh) 2015-11-03 2022-08-23 詹森生物科技公司 特异性结合pd-1的抗体及其用途
UA125611C2 (uk) 2015-12-14 2022-05-04 Макродженікс, Інк. Біспецифічні молекули, що мають імунореактивність відносно pd-1 і ctla-4, і способи їх застосування
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2017205721A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
MX2019000443A (es) 2016-07-14 2019-06-20 Squibb Bristol Myers Co Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos.
MA46113A (fr) * 2016-11-01 2019-07-10 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de lymphocyte t et la protéine 3 de mucine (tim-3)
CN110382000A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗tim-3抗体治疗癌症的方法
WO2018156777A1 (en) * 2017-02-22 2018-08-30 Sutro Biopharma, Inc. Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
EP3585431A4 (en) 2017-02-24 2020-12-16 MacroGenics, Inc. BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES
BR112019017743A2 (pt) 2017-02-28 2020-04-07 Sanofi Sa rna terapêutico
US11225523B2 (en) * 2017-06-01 2022-01-18 Compugen Ltd. Triple combination antibody therapies
WO2018222975A1 (en) * 2017-06-02 2018-12-06 Rgenix, Inc. Methods for the treatment of cancer
EP3634995A4 (en) 2017-06-05 2021-06-09 Janssen Biotech, Inc. Antibodies specific to PD-1 binding and method of use
GB2567613A (en) * 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
BR112020000227A2 (pt) 2017-07-06 2020-09-29 Merus N.V. anticorpos biespecíficos anti pd1-anti tim3
EA202090401A1 (ru) 2017-07-28 2020-05-18 Фейнз Терапьютикс, Инк. Анти-tim-3 антитела и их применение
EP4029877B1 (en) 2017-08-03 2024-01-17 Amgen Inc. Interleukin-21 muteins and methods of treatment
US11787859B2 (en) 2017-08-28 2023-10-17 Bristol-Myers Squibb Company TIM-3 antagonists for the treatment and diagnosis of cancers
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
AU2018348350B2 (en) 2017-10-11 2024-05-02 Aurigene Oncology Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
SG11202003280SA (en) 2017-10-24 2020-05-28 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+ cells
AU2018354189A1 (en) 2017-10-24 2020-04-23 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
JP7378395B2 (ja) 2017-11-06 2023-11-13 オーリジーン オンコロジー リミテッド 免疫調節のためのコンジョイントセラピー
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
CN109971713B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 稳定表达PD-1抗体的Muc1特异性CAR-T细胞及其用途
EP3737700A1 (en) * 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019140196A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Anti-pd-1 antibodies and methods of treatment
GB201800649D0 (en) * 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2019143607A1 (en) 2018-01-16 2019-07-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
US12398209B2 (en) * 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
US11827697B2 (en) 2018-02-11 2023-11-28 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof
CN110144011B (zh) * 2018-02-14 2020-06-23 上海洛启生物医药技术有限公司 针对t淋巴细胞免疫球蛋白黏蛋白3的单域抗体
EP3759125A4 (en) * 2018-02-28 2021-12-08 Dana-Farber Cancer Institute, Inc. METHOD OF CANCER TREATMENT USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNCHECKPOINT BLOCKING REAGENTS
WO2019183551A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
US11807683B2 (en) 2018-04-12 2023-11-07 Nanjing Leads Biolabs Co., Ltd. Antibody binding TIM-3 and use thereof
JP7466459B2 (ja) 2018-04-17 2024-04-12 セルデックス セラピューティクス インコーポレイテッド 抗ｃｄ２７および抗ｐｄ－ｌ１抗体ならびに二重特異性構築物
JP7328324B2 (ja) * 2018-04-24 2023-08-16 アンプソース・バイオファーマ・シャンハイ・インコーポレイテッド Ｔｉｍ－３に対する抗体およびその使用
US11866499B2 (en) * 2018-05-24 2024-01-09 Janssen Biotech, Inc. Monospecific and multispecific anti-TMEFF2 antibodies and their uses
EP3818085A4 (en) 2018-06-01 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. COMPOSITIONS AND THEIR USES FOR TREATING A DISEASE OR CONDITION
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
IL319456A (en) 2018-06-20 2025-05-01 Incyte Holdings Corp ANTI-PD-1 ANTIBODIES AND THEIR USES
EP3826673A4 (en) * 2018-07-26 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. COMPOSITIONS AND METHODS FOR IMAGING
CA3108812A1 (en) * 2018-08-20 2020-02-27 Jiangsu Hengrui Medicine Co., Ltd. Use of tim-3 antibody in preparation of medicines for treating tumors
CN112638944A (zh) 2018-08-23 2021-04-09 西进公司 抗tigit抗体
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020093023A1 (en) * 2018-11-01 2020-05-07 Merck Patent Gmbh Anti-tim-3 antibodies
EP3666905A1 (en) 2018-12-11 2020-06-17 Sanofi E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer
EP3894442A4 (en) * 2018-12-12 2022-08-10 Wuxi Biologics Ireland Limited ANTI-TIM-3 ANTIBODIES AND USES THEREOF
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
CN111349162A (zh) * 2018-12-21 2020-06-30 神州细胞工程有限公司 人源化抗pd-1抗体及其用途
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
KR20210118870A (ko) 2019-01-21 2021-10-01 사노피 진행성 단계의 고형 종양 암에 대한 치료용 rna 및 항-pd1 항체
JP7538130B2 (ja) 2019-01-23 2024-08-21 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 抗ｐｄ－ｌ１ダイアボディおよびその使用
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
WO2020177627A1 (zh) * 2019-03-02 2020-09-10 上海一宸医药科技有限公司 一种双特异抗体
EP3958909A4 (en) * 2019-04-24 2024-01-10 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
JP2022530443A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド 抗ｃｄ１１７抗体薬物複合体およびその使用
JP2022534981A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
KR20220016156A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
KR20220041079A (ko) 2019-06-18 2022-03-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv) 백신 및 항-pd-1 항체의 조합
WO2020255011A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
AU2020296124A1 (en) * 2019-06-21 2022-01-27 Single Cell Technology, Inc. Anti-TIM-3 antibodies
TWI889320B (zh) 2019-07-05 2025-07-01 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
CA3146777A1 (en) * 2019-08-02 2021-02-11 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-pd-1 antibody and pharmaceutical use thereof
EP4011918A4 (en) 2019-08-08 2023-08-23 ONO Pharmaceutical Co., Ltd. DUAL SPECIFIC PROTEIN
US20220298252A1 (en) * 2019-08-30 2022-09-22 Pelican Therapeutics, Inc. Methods of treating cancer using tnfrsf25 antibodies
CN112587666A (zh) * 2019-09-17 2021-04-02 广州再极医药科技有限公司 用于治疗癌症的pd-1/pd-l1相互作用的小分子抑制剂和抗pd-1抗体的组合
US20230046904A1 (en) * 2019-09-17 2023-02-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Combination of small molecule inhibitor of the pd-1/pd-l1 interaction and anti-pd-1 antibody for treating cancer
WO2021087105A1 (en) * 2019-10-30 2021-05-06 Duke University Immunotherapy with combination therapy comprising an immunotoxin
CN115298549A (zh) * 2019-11-05 2022-11-04 百时美施贵宝公司 M蛋白测定及其用途
TWI900527B (zh) 2020-02-12 2025-10-11 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
AU2021242305A1 (en) * 2020-03-26 2022-10-20 Cureimmune Therapeutics Inc. Anti-PD-1 antibodies and methods of use
WO2021219048A1 (zh) * 2020-04-30 2021-11-04 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用
IL297963A (en) 2020-05-07 2023-01-01 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
CN111690070A (zh) * 2020-05-13 2020-09-22 深圳市众循精准医学研究院 一种sPD-1-Fc-sTGFβRII融合蛋白及其应用
WO2021226984A1 (zh) * 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
CN116209676A (zh) 2020-06-22 2023-06-02 恩格姆生物制药公司 Lair-1结合剂及其使用方法
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4185609A4 (en) * 2020-07-21 2025-09-03 Scripps Research Inst Disruption of CD28-SIALOSIDE LIGAND Complexes to Improve T Cell Activation
GB202011996D0 (en) 2020-07-31 2020-09-16 Adorx Therapeutics Ltd Antagonist compounds
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
CN114349867B (zh) * 2020-10-14 2024-05-28 广东菲鹏制药股份有限公司 融合蛋白及其应用
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
GB202019622D0 (en) 2020-12-11 2021-01-27 Adorx Therapeutics Ltd Antagonist compounds
US20250270304A1 (en) * 2020-12-23 2025-08-28 Phenomic Ai Anti-activin antibodies and methods of using the same
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
DK4267105T3 (da) 2020-12-28 2025-05-19 Bristol Myers Squibb Co Antistofsammensætninger og fremgangsmåder til anvendelse deraf
EP4282413A4 (en) * 2021-01-21 2024-12-25 Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. COMPOSITION AND METHOD FOR TREATING TUMORS
EP4305051A4 (en) * 2021-03-08 2025-06-04 Shattuck Labs, Inc. CHIMERIC PROTEINS USEFUL IN AUTOIMMUNITY
WO2022212516A1 (en) * 2021-03-31 2022-10-06 Merus N.V. Multispecific binding moieties comprising novel pd-1 binding domains
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
CN117377692A (zh) 2021-04-23 2024-01-09 苏州逻晟生物医药有限公司 Tim-3-靶向抗体及其用途
CA3216034A1 (en) 2021-04-25 2022-11-03 Xiaofeng Yang Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof
US20250059267A1 (en) * 2021-05-14 2025-02-20 Phenomic Ai Combination therapy for treatment of tumors comprising cancer-associated fibroblasts
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
JP2024533998A (ja) * 2021-08-10 2024-09-18 ザ ジョンズ ホプキンス ユニバーシティ 癌の治療のための組成物及び方法
AU2022333321A1 (en) * 2021-08-27 2024-04-11 Janssen Biotech, Inc. Anti-psma antibodies and uses thereof
TW202328195A (zh) * 2021-09-15 2023-07-16 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｐｄ－１的蛋白及其醫藥用途
JP2024541076A (ja) * 2021-11-09 2024-11-06 ヤンセン バイオテツク，インコーポレーテツド Ｔ細胞受容体リガンドを特定するためのマイクロ流体共カプセル化デバイス、システム、及び方法
EP4456907A1 (en) 2021-12-30 2024-11-06 NeoImmuneTech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
US20250101084A1 (en) * 2022-01-07 2025-03-27 Trustees Of Dartmouth College Compositions and methods for preventing or ameliorating neonatal hsv infection
GB2615307A (en) 2022-01-28 2023-08-09 Adorx Therapeutics Ltd Antagonist compounds
IL314641A (en) * 2022-02-10 2024-09-01 Nextpoint Therapeutics Inc Substances that attach to T cells and NK cells
CN118786147A (zh) * 2022-03-02 2024-10-15 诺和诺德医疗保健公司 每月一次施用fviii模拟双特异性抗体的方法
EP4493575A1 (en) 2022-03-18 2025-01-22 Bristol-Myers Squibb Company Methods of isolating polypeptides
IL317319A (en) 2022-06-02 2025-01-01 Bristol Myers Squibb Co Antibody compounds and methods of using them
EP4615485A1 (en) 2022-11-07 2025-09-17 NeoImmuneTech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024126750A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Methods for treating cancer
IL322179A (en) 2023-01-30 2025-09-01 Kymab Ltd Antibodies
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024215682A1 (en) 2023-04-10 2024-10-17 Taris Biomedical Llc Gemcitabine for use in methods of treating high-risk non-muscle invasive bladder cancer unresponsive to bacillus calmette-guerin therapy
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025094087A1 (en) 2023-10-30 2025-05-08 Johnson & Johnson Enterprise Innovation Inc. Safe administration of a2a rector antagonist
WO2025098364A1 (zh) * 2023-11-06 2025-05-15 南京蓬勃生物科技有限公司 靶向人源pd-l1的全人源抗体
WO2025111989A1 (zh) * 2023-11-30 2025-06-05 华东师范大学 嵌合抗原受体及其应用
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025195358A1 (zh) * 2024-03-19 2025-09-25 江苏恒瑞医药股份有限公司 Pd-1结合蛋白及医药用途

Family Cites Families (345)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541606A (en) 1895-06-25 Sealed package
US226A (en) 1837-06-03 Samuel goss
US7709A (en) 1850-10-08 Chas S Gaylord Improved spring-grapple
EP0090505B1 (en) 1982-03-03 1990-08-08 Genentech, Inc. Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ES2059558T3 (es) 1987-06-17 1994-11-16 Sandoz Ag Ciclosporins y su uso como productos farmaceuticos.
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
IL108501A (en) 1994-01-31 1998-10-30 Mor Research Applic Ltd Antibodies and pharmaceutical compositions containing them
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5688690A (en) 1994-09-16 1997-11-18 The Wistar Institute Of Anatomy And Biology Human cytotoxic lymphocyte signal transduction surface protein (P38) and monoclonal antibodies thereto
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
WO1997010354A1 (fr) * 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
JP2002514895A (ja) 1995-09-28 2002-05-21 アレクション、ファーマスーティカルズ、インコーポレーテッド ブタ細胞相互作用タンパク質
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
AU4055697A (en) 1996-08-16 1998-03-06 Schering Corporation Mammalian cell surface antigens; related reagents
US6140076A (en) 1996-12-06 2000-10-31 Schering Corporation Ig superfamily `dlair` receptors expressed in monocytes
US20060280140A9 (en) * 1997-02-06 2006-12-14 Mahany Ronald L LOWER POWER WIRELESS BEACONING NETWORK SUPPORTING PROXIMAL FORMATION, SEPARATION AND REFORMATION OF WIRELESS LOCAL AREA NETWORKS (LAN's), AS TERMINALS MOVE IN AND OUT RANGE OF ONE ANOTHER
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
SI0973804T1 (sl) 1997-04-07 2007-06-30 Genentech Inc Proti-VEGF protitelesa
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CA2304208A1 (en) * 1997-09-19 1999-03-25 Dana-Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
WO1999020758A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
AU2591599A (en) 1998-02-09 1999-08-23 Genentech Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
DE19835635C2 (de) 1998-08-06 2000-05-25 Knorr Bremse Systeme Relaisventil für Druckluftbremssysteme von Schienenfahrzeugen
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7888477B2 (en) 1998-12-17 2011-02-15 Corixa Corporation Ovarian cancer-associated antibodies and kits
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
CA2378179A1 (en) 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
WO2001049698A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
CA2398998C (en) 2000-02-01 2014-04-22 Tanox, Inc. Cd40-binding apc-activating molecules
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US6696620B2 (en) * 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
CA2412377A1 (en) 2000-06-06 2001-12-13 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
CA2412494C (en) 2000-06-22 2012-10-23 Genentech, Inc. Agonist anti-trk-c monoclonal antibodies
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
WO2002060954A1 (en) 2001-01-12 2002-08-08 Karolinska Innovations Ab Materials and methods for treatment of hepatitis c
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
KR100926194B1 (ko) 2001-10-30 2009-11-09 노파르티스 아게 Ｆｌｔ３ 수용체 티로신 키나아제 활성의 억제제로서의스타우로스포린 유도체
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
PA8569301A1 (es) 2002-03-13 2004-10-08 Array Biopharma Inc "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimidazole derivatives as mek inhibitors"
WO2003106498A2 (en) 2002-06-13 2003-12-24 Crucell Holland, B.V. Agonistic binding molecules to the human ox40 receptor
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
EP1560593B1 (en) 2002-10-25 2016-04-20 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
ATE466885T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
EA009919B1 (ru) 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
WO2004072117A2 (en) 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
US20070048740A1 (en) * 2003-02-14 2007-03-01 Research Association For Biotechnology Full-length cDNA
US20050009136A1 (en) * 2003-02-19 2005-01-13 Dyax Corporation PAPP-A ligands
CA2522567C (en) * 2003-04-17 2011-08-23 Cytec Technology Corp. Composition and process for the solvent extraction of metals using aldoxime or ketoxime extractants
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
NZ543654A (en) 2003-05-23 2009-05-31 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
RS20170595A1 (sr) 2003-05-30 2017-09-29 Genentech Inc Tretman sa anti-vegf antitelima
DE602004030464D1 (de) 2003-07-02 2011-01-20 Innate Pharma Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2005039549A1 (en) 2003-10-27 2005-05-06 Novartis Ag Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
NZ547633A (en) 2003-11-06 2010-08-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005044857A1 (ja) 2003-11-11 2005-05-19 Chugai Seiyaku Kabushiki Kaisha ヒト化抗cd47抗体
GB2408508A (en) * 2003-11-28 2005-06-01 Astrazeneca Ab Apolipoprotein antibodies
EP1692318A4 (en) 2003-12-02 2008-04-02 Genzyme Corp COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
CA2553433A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
PL2298768T3 (pl) 2004-06-11 2013-03-29 Japan Tobacco Inc Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
WO2006053110A2 (en) 2004-11-10 2006-05-18 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US8188232B1 (en) 2004-11-15 2012-05-29 Washington University In St. Louis Compositions and methods for modulating lymphocyte activity
KR101387781B1 (ko) * 2005-01-07 2014-04-21 렉시컨 파마슈티컬스 인코퍼레이티드 앤지오포이에틴-유사 단백질 4 (ａｎｇｐｔｌ４) 에 대한단일클론 항체
US8119385B2 (en) * 2005-03-04 2012-02-21 Bp Corporation North America Inc. Nucleic acids and proteins and methods for making and using them
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
EP2345723A1 (en) * 2005-03-25 2011-07-20 National Research Council Of Canada Method for isolation of soluble polypeptides
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN101237882B (zh) 2005-05-26 2012-08-15 西雅图基因公司 人源化的抗-cd40抗体及其使用方法
KR101514463B1 (ko) 2005-06-08 2015-04-28 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
JP2006345852A (ja) * 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
JP4557003B2 (ja) 2005-07-01 2010-10-06 株式会社村田製作所 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
CN101248089A (zh) 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
KR20130023356A (ko) * 2005-07-18 2013-03-07 메다렉스, 인코포레이티드 인간 항-ｂ7ｒｐ1 중화 항체
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
JP5350793B2 (ja) * 2005-08-31 2013-11-27 メルク・シャープ・アンド・ドーム・コーポレーション 改変抗ｉｌ−２３抗体
SG170080A1 (en) 2005-12-08 2011-04-29 Medarex Inc Human monoclonal antibodies to o8e
SI3184526T1 (sl) 2005-12-13 2019-03-29 Incyte Holdings Corporation Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CN101495136A (zh) 2006-02-15 2009-07-29 英克隆系统公司 抗体配制品
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
PE20110218A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
AR064801A1 (es) 2006-08-18 2009-04-29 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
CA2660546A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
ATE550355T1 (de) * 2006-09-29 2012-04-15 Hoffmann La Roche Antikörper gegen ccr5 und ihre verwendung
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
KR20090088891A (ko) 2006-11-15 2009-08-20 메다렉스, 인코포레이티드 비티엘에이에 대한 인간 단일클론 항체 및 이용 방법
CN103641833A (zh) 2006-12-08 2014-03-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008083228A2 (en) 2006-12-27 2008-07-10 The Johns Hopkins University Compositions and methods for treating inflammation and auto-immune diseases
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
CN101801413A (zh) 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
AU2008282218A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
EP2195347A1 (en) 2007-08-17 2010-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
CA2704357C (en) * 2007-11-02 2016-06-21 Novartis Ag Improved nogo-a binding molecules and pharmaceutical use thereof
EP2851374B1 (en) 2007-12-14 2017-05-03 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
PL2690101T3 (pl) 2007-12-19 2015-12-31 Genentech Inc 5-anilinoimidazopirydyny i sposoby zastosowania
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
FR2929946B1 (fr) 2008-04-11 2010-05-28 Pf Medicament Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
WO2009134389A2 (en) 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
AU2009266873A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc TGF-beta antagonist multi-target binding proteins
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CA2734802C (en) 2008-08-22 2016-05-31 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
EP2344474B1 (en) 2008-09-02 2015-09-23 Novartis AG Picolinamide derivatives as kinase inhibitors
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US9181342B2 (en) 2008-09-12 2015-11-10 Isis Innovation Limited PD-1 specific antibodies and uses thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
EP2347038A4 (en) 2008-10-14 2013-06-12 Janssen Biotech Inc METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
AU2009319048B2 (en) 2008-11-28 2014-01-30 Novartis Ag Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor
HUE034832T2 (hu) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
US20110268741A1 (en) 2009-01-05 2011-11-03 The Johns Hopkins University Immunotherapy for Contact Dermatitis Using Co-Signal Regulation
US20120017292A1 (en) 2009-01-16 2012-01-19 Kovalic David K Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules to generate transgene plants with enhanced agronomic traits
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
AR075989A1 (es) * 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
BRPI1015350B1 (pt) 2009-04-30 2021-08-24 Tel Hashomer Medical Research Infrastructure And Services Ltd Célula do hibridoma, anticorpo isolado ceacam1 ou fragmento de anticorpo, método para diagnosticar um câncer em um sujeito em necessidade do mesmo e composição farmacêutica
RU2420587C2 (ru) * 2009-06-25 2011-06-10 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА И Fab, СВЯЗЫВАЮЩИЕСЯ С АНТИГЕНОМ F1 ИЗ Yersinia pestis, И СПОСОБ ИХ ПОЛУЧЕНИЯ С ИСПОЛЬЗОВАНИЕМ ДРОЖЖЕЙ
KR101360725B1 (ko) 2009-06-26 2014-02-07 노파르티스 아게 Ｃｙｐ17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체
EA201270228A1 (ru) 2009-07-31 2012-09-28 Медарекс, Инк. Полноценные человеческие антитела к btla
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
AU2010289677B2 (en) 2009-09-03 2014-07-31 Merck Sharp & Dohme Llc Anti-GITR antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
SI3279215T1 (sl) * 2009-11-24 2020-07-31 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
CA2782218C (en) 2009-11-30 2018-07-31 Janssen Biotech, Inc. Antibody fc mutants with ablated effector functions
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CN105693861A (zh) 2009-12-29 2016-06-22 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
WO2011103426A2 (en) 2010-02-19 2011-08-25 The Board Of Regents Of The University Of Oklahoma Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
HUE045487T2 (hu) 2010-03-04 2019-12-30 Macrogenics Inc B7-H3-ra reaktív antitestek, immunológiailag aktív fragmenseik és alkalmazásaik
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
EP2566514A4 (en) * 2010-05-03 2013-11-27 Abbvie Inc METHODS OF INHIBITING FIBROSIS WITH ANTI-PAI-1 ANTIBODIES
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
KR101846590B1 (ko) 2010-06-11 2018-04-09 교와 핫꼬 기린 가부시키가이샤 항 ｔｉｍ-3 항체
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
SI2606070T1 (sl) 2010-08-20 2017-04-26 Novartis Ag Protitelesa za receptor 3 epidermalnega rastnega faktorja (HER3)
SI2609118T1 (sl) 2010-08-23 2017-05-31 The Board Of Regents, The University Of Texas System Protitelesa proti ox40 in postopki uporabe istih
WO2013028231A1 (en) 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
JP6105470B2 (ja) 2010-09-09 2017-03-29 ファイザー・インク ４−１ｂｂ結合分子
JP6126991B2 (ja) 2010-09-27 2017-05-10 ヤンセン バイオテツク，インコーポレーテツド ヒトｉｉ型コラーゲンに結合する抗体
PT2635601T (pt) * 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
US9562109B2 (en) 2010-11-05 2017-02-07 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
DE102010052101A1 (de) 2010-11-20 2012-05-24 Schaeffler Technologies Gmbh & Co. Kg Lagervorrichtung mit einem Fanglager
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
CN102740477B (zh) 2011-03-31 2016-03-02 华为技术有限公司 时分双工系统中子帧配置的方法、基站及用户设备
HUE039209T2 (hu) 2011-03-31 2018-12-28 Merck Sharp & Dohme Antitestek stabil formulációi emberi programozott halálreceptor PD-1 ellen és ezzel kapcsolatos kezelések
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
WO2012145568A1 (en) 2011-04-21 2012-10-26 Albert Einstein College Of Medicine Of Yeshiva University Antibodies to human b7x for treatment of metastatic cancer
US20140234320A1 (en) * 2011-06-20 2014-08-21 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
WO2013006490A2 (en) * 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
BR112014004937A2 (pt) 2011-09-07 2017-06-20 Deutsches Krebsforsch método para tratar e/ou prevenir um câncer dependente de ligante de ahr natural e inibidor de ahr
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AP3613A (en) 2012-05-15 2016-02-29 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 abl1abl2 bcr-abl1
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
JP6078640B2 (ja) 2012-05-15 2017-02-08 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
WO2013171641A1 (en) 2012-05-15 2013-11-21 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
ES2665539T3 (es) 2012-05-15 2018-04-26 Novartis Ag Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1
EP3202419A1 (en) 2012-06-06 2017-08-09 OncoMed Pharmaceuticals, Inc. Pvrig binding agents that modulate the hippo pathway and uses thereof
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
KR20150023811A (ko) * 2012-06-21 2015-03-05 컴퓨젠 엘티디. 암의 치료를 위한 lsr 항체 및 그의 용도
JP2015525781A (ja) 2012-07-31 2015-09-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答の調節
WO2014031718A1 (en) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
HK1214765A1 (zh) 2012-11-08 2016-08-05 Novartis Ag 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途
SG11201503938VA (en) 2012-11-21 2015-06-29 Janssen Biotech Inc BISPECIFIC EGFR/c-Met ANTIBODIES
JP2016501221A (ja) 2012-11-28 2016-01-18 ノバルティス アーゲー 併用療法
JP2016509582A (ja) 2012-12-19 2016-03-31 アンプリミューン， インコーポレイテッド 抗ヒトｂ７−ｈ４抗体およびその使用
MX387324B (es) 2013-01-10 2025-03-18 Genmab Bv Variantes de regiones fc de igg1 de humano y usos de las mismas.
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US10150813B2 (en) 2013-03-14 2018-12-11 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
LT2970473T (lt) 2013-03-14 2017-10-25 Bristol-Myers Squibb Company Dr5 agonisto ir anti-pd-1 antagonisto derinys ir naudojimo būdai
EP2970451A1 (en) 2013-03-14 2016-01-20 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
EA028033B1 (ru) 2013-03-14 2017-09-29 Новартис Аг 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантного idh
LT2970980T (lt) 2013-03-15 2018-10-25 Janssen Biotech, Inc. Gamybos būdas kontroliuoti c galinio lizino, galaktozės ir sialo rūgšties kiekį rekombinantiniuose baltymuose
US20160032014A1 (en) 2013-03-15 2016-02-04 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
AU2014238546C1 (en) 2013-03-18 2019-01-17 Biocerox Products B.V. Humanized anti-CD134 (OX40) antibodies and uses thereof
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
JP6603209B2 (ja) 2013-05-10 2019-11-06 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾
US10005839B2 (en) 2013-05-17 2018-06-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonist of the BTLA/HVEM interaction for use in therapy
HK1221964A1 (zh) 2013-05-31 2017-06-16 Sorrento Therapeutics, Inc. 与pd-1结合的抗原结合蛋白
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
KR20220042248A (ko) 2013-07-16 2022-04-04 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
WO2015013389A2 (en) 2013-07-24 2015-01-29 Dana-Farber Cancer Institute, Inc. Anti-galectin-1 (gal1) monoclonal antibodies and fragments thereof for neutralizing gal1
FI3036258T3 (fi) 2013-08-22 2023-09-22 Council Queensland Inst Medical Res Immunoreseptorin modulointi syövän ja virusinfektioiden hoitamiseksi
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
PL3702373T3 (pl) 2013-09-13 2022-12-05 Beigene Switzerland Gmbh Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne
CN104558177B (zh) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
CN105848680A (zh) * 2013-10-25 2016-08-10 药品循环有限责任公司 使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗
BR112016010224A2 (pt) * 2013-11-05 2018-05-02 Cognate Bioservices, Inc. combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
CN105026428B (zh) 2013-12-12 2018-01-16 上海恒瑞医药有限公司 PD‑l抗体、其抗原结合片段及其医药用途
CA2933881A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015091910A2 (en) 2013-12-20 2015-06-25 Intervet International B.V. Caninized antibodies
US9456612B2 (en) * 2013-12-26 2016-10-04 Zimplistic Pte. Ltd. Dry flour dispensing apparatus and using the same for a food preparation appliance
CN103721255A (zh) * 2014-01-07 2014-04-16 苏州大学 共同阻断pd-1和tim-3信号通路在抗胃癌治疗中的用途
WO2015112534A2 (en) * 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US10392438B2 (en) 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EP3168236B1 (en) 2014-07-09 2019-09-04 Nippon Zenyaku Kogyo Co., Ltd. Anti-canine pd-1 antibody or anti-canine pd-l1 antibody
EP3171892B1 (en) 2014-07-22 2021-11-24 Apollomics Inc. Anti-pd-1 antibodies
SG11201700672YA (en) 2014-08-05 2017-02-27 MabQuest SA Immunological reagents binding to pd-1
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
WO2016077397A2 (en) 2014-11-11 2016-05-19 Sutro Biopharma, Inc. Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3916017A1 (en) 2014-12-22 2021-12-01 PD-1 Acquisition Group, LLC Anti-pd-1 antibodies
CN105061597B (zh) 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
CA3006224A1 (en) 2015-06-23 2016-12-29 Memorial Sloan-Kettering Cancer Center Novel pd-1 immune modulating agents
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
SMT202400127T1 (it) 2015-06-24 2024-05-14 Janssen Biotech Inc Modulazione immunitaria e trattamento di tumori solidi con anticorpi che si legano specificamente a cd38
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
CN106699888B (zh) 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
PT3456346T (pt) 2015-07-30 2021-09-28 Macrogenics Inc Moléculas de ligação pd-1 e lag-3 e respetivos métodos de utilização
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
UA124259C2 (uk) 2015-09-28 2021-08-18 Сужоу Санкадіа Байофармасьютікалз Ко., Лтд. Фармацевтичне одержання стабільного анти-pd-1 антитіла та його застосування в медицині
WO2017058115A1 (en) 2015-09-29 2017-04-06 Asia Biotech Pte. Ltd. Pd-1 antibodies and uses thereof
EA201890790A1 (ru) 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
EP3150636A1 (en) * 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
DK3356404T3 (da) 2015-10-02 2021-10-25 Hoffmann La Roche Anti-pd1-antistoffer og fremgangsmåder til anvendelse
US10287352B2 (en) 2015-10-02 2019-05-14 Hoffman-La Roche Inc. Bispecific antibodies specific for PD1 and TIM3
KR102897330B1 (ko) 2015-10-02 2025-12-05 르 라보레또레 쎄르비에르 항-pd-1 항체 및 조성물
CN106632674B (zh) 2015-10-30 2018-11-16 泽达生物医药有限公司 一种抗pd-1单克隆抗体、其药物组合物及其用途
CN108697791B (zh) 2015-11-03 2022-08-23 詹森生物科技公司 特异性结合pd-1的抗体及其用途
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
TWI782898B (zh) 2015-11-18 2022-11-11 美商默沙東有限責任公司 Pd1／ctla4結合劑
EA039865B1 (ru) 2016-01-11 2022-03-22 Универзитет Цюрих Иммуностимулирующее гуманизированное моноклональное антитело против интерлейкина-2 человека и слитый белок
LT3452053T (lt) 2016-05-06 2023-02-10 Taris Biomedical Llc Apatinių šlapimo takų urotelinio vėžio gydymo būdas
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
WO2018026248A1 (ko) 2016-08-05 2018-02-08 주식회사 와이바이오로직스 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
WO2018027524A1 (en) 2016-08-09 2018-02-15 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibody formulation
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
DK3512547T3 (en) 2016-09-14 2020-12-07 Abbvie Biotherapeutics Inc Anti-pd-1-antistoffer
JP7164528B2 (ja) 2016-09-14 2022-11-01 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド Ｐｄ－１に特異的に結合する可能な抗体及びその機能的断片
WO2018053709A1 (en) 2016-09-21 2018-03-29 Wuxi Biologics (Shanghai) Co., Ltd. The novel monoclonal antibodies to programmed death 1 (pd-1)
DE102017211373B4 (de) 2017-07-04 2025-05-08 Schaeffler Technologies AG & Co. KG Induktive Ladevorrichtung für ein elektrisch antreibbares Kraftfahrzeug und Betriebsverfahren für die Ladevorrichtung

Also Published As

Publication number Publication date
EP3370769A4 (en) 2019-05-22
PT3370768T (pt) 2022-04-21
MA43186B1 (fr) 2022-03-31
JP2019500891A (ja) 2019-01-17
BR112018008867A2 (en) 2018-11-06
CN108430509B (zh) 2022-09-16
CN108430509A (zh) 2018-08-21
BR112018008891A2 (en) 2018-11-06
JP2022031666A (ja) 2022-02-22
JP2022036949A (ja) 2022-03-08
ES2908376T3 (es) 2022-04-28
BR112018008891A8 (pt) 2019-02-26
ZA201803669B (en) 2022-01-26
HUE057837T2 (hu) 2022-06-28
CN114478790A (zh) 2022-05-13
HRP20220436T1 (hr) 2022-05-27
MX2018005546A (es) 2019-07-18
CN108473584B (zh) 2022-01-14
BR112018008904A2 (en) 2018-11-27
LT3370768T (lt) 2022-05-25
GT201800090A (es) 2019-11-13
JP2022078101A (ja) 2022-05-24
KR20180069070A (ko) 2018-06-22
MD3370768T2 (ro) 2022-07-31
US10894830B2 (en) 2021-01-19
TW201730213A (zh) 2017-09-01
EP3370768B9 (en) 2022-03-16
WO2017079115A1 (en) 2017-05-11
EP3370769A1 (en) 2018-09-12
US20170121409A1 (en) 2017-05-04
CN108697791A (zh) 2018-10-23
PE20181326A1 (es) 2018-08-20
EP3371226A4 (en) 2019-07-17
RS63125B1 (sr) 2022-05-31
PL3370768T3 (pl) 2022-06-13
ECSP18041833A (es) 2018-06-30
MY198562A (en) 2023-09-05
KR20180072821A (ko) 2018-06-29
CN108697791B (zh) 2022-08-23
JP7335374B2 (ja) 2023-08-29
KR20250099459A (ko) 2025-07-01
SI3370768T1 (sl) 2022-04-29
WO2017079116A2 (en) 2017-05-11
EP4046655A1 (en) 2022-08-24
JO3798B1 (ar) 2021-01-31
EP4046655A9 (en) 2023-04-12
EP3370768A4 (en) 2019-07-24
MX2018005551A (es) 2018-11-09
EA201891093A1 (ru) 2018-10-31
AU2016348388B2 (en) 2023-11-30
EP3371226A2 (en) 2018-09-12
MA43186A (fr) 2021-04-07
IL258909B2 (en) 2023-06-01
SMT202200118T1 (it) 2022-05-12
TWI772275B (zh) 2022-08-01
JP2019500892A (ja) 2019-01-17
PH12018500906B1 (en) 2024-06-14
CN108473584A (zh) 2018-08-31
PH12018500906A1 (en) 2018-11-05
MX2018005550A (es) 2019-07-18
AU2016350700A1 (en) 2018-05-17
CO2018005614A2 (es) 2018-05-31
DK3370768T3 (da) 2022-03-21
CY1125267T1 (el) 2024-02-16
EP3370768B1 (en) 2022-01-12
KR102828417B1 (ko) 2025-07-02
CN116059344A (zh) 2023-05-05
WO2017079116A3 (en) 2017-07-20
US20210277110A1 (en) 2021-09-09
JP2019500893A (ja) 2019-01-17
EP3370768A1 (en) 2018-09-12
JP7051692B2 (ja) 2022-04-11
CA3004138A1 (en) 2017-05-11
AU2016348388A1 (en) 2018-05-17
US20250215079A1 (en) 2025-07-03
CA3004134A1 (en) 2017-05-11
IL258909A (en) 2018-06-28
CR20180234A (es) 2018-09-11
SV2018005684A (es) 2018-09-25
KR20180069071A (ko) 2018-06-22
NI201800055A (es) 2019-03-29
US12173064B2 (en) 2024-12-24
NZ741953A (en) 2025-03-28
AR106583A1 (es) 2018-01-31
UA126896C2 (uk) 2023-02-22
WO2017079112A1 (en) 2017-05-11
SG11201803520PA (en) 2018-05-30
AU2016348391A1 (en) 2018-05-17
BR112018008867A8 (pt) 2019-02-26
CA3004117A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
CL2018001177A1 (es) Anticuerpos vinculados especificamente a pd-1 y sus usos.
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20210115A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20180604A1 (es) Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana)
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
CU24636B1 (es) Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
CU24568B1 (es) Anticuerpo inhibidor de masp-3
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
NZ731735A (en) Anti-pd-1 antibodies and methods of use thereof
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
NZ738979A (en) Pd-1 antibodies
GEAP202214712A (en) Pd-1-binding molecules and methods of use thereof
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
NZ728749A (en) Anti-pd-l1 antibodies
PE20170665A1 (es) Anticuerpos anti-tau humanizados
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
PE20150002A1 (es) Anticuerpos anti-fcrn
PE20150159A1 (es) Composiciones y metodos para anticuerpos que actuan sobre el factor p